TOLOCHENAZ, Switzerland, March 7, 2016 /PRNewswire/ --
European innovation delivers titanium family of cages to support twin surgical objectives of bone fusion and sagittal realignment for improved patients’ outcomes.
Medtronic PLC (NYSE: MDT), the global leader in medical technology, today announced the launch of AVILA™, its new family of interbody fusion devices for L2-S1 levels in open and minimally invasive ALIF and OLIF procedures.
AVILA™ addresses the multiple needs of interbody fusion procedures with its smart cage design. A wide range of lordotic options up to 24° and an anatomical shape provide the support to realign the spine. Titanium alloy properties are combined with large inner and lateral windows for bone grafting and post-operative fusion assessment.
Dr. Frank Hassel, orthopaedic surgeon at Loretto-Krankenhaus Hospital in Freiburg, Germany, commented after his first surgery with AVILA™: "AVILA™ is straightforward to use, which eases even complex surgeries. I like the strong connection between cage and inserter during the impaction. I was able to adequately correct the lordosis and place a large amount of bone graft. These are necessary aspects to improve fusion and stability outcomes."
AVILA™ is provided in a compact kit with a unique dismountable inserter, allowing for easier sterilisation, making operating room management faster and reducing the time and cost of surgery.
Sharrolyn Transfeldt Josse, Medtronic Vice-President Spine & Pain Europe, remarked: "AVILA™ exists as a result of our collaboration with surgeons, for whom the goals of spinal surgery are increasingly two-fold; achieve fusion and restore sagittal alignment. AVILA™ addresses those objectives, and we are proud this product was conceived and developed entirely at our Product Development Office in Switzerland."
AVILA™ is the newest addition to Medtronic spinal portfolio, and it integrates with PYRAMID®+4 Anterior Lumbar Plate System, posterior fixation systems such as CD HORIZON® LONGITUDE® II and with the extensive biologic portfolio including Grafton® Demineralized Bone Matrix and Mastergraft®.
AVILA™ interbody fusion devices have CE-Mark for use for interbody fusion with autogenous bone graft and/or bone graft substitute in adults with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. Eligible patients must have had at least six months of non-operative treatment for this condition. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved levels. These devices are intended for use with supplemental fixation instrumentation, which has been cleared for use in the lumbar spine.
AVILA™ family of interbody fusion devices incorporates technology developed by Gary K. Michelson, M.D.
About the Spinal Business at Medtronic
Medtronic's Spinal business, based in Memphis, Tenn., is the global leader in today's spine market and is committed to advancing the treatment of spinal conditions. Medtronic's Spinal business collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art therapies for spinal, neurological, orthopaedic and oral maxillofacial conditions. Medtronic is committed to developing affordable, minimally invasive procedures that provide lifestyle friendly surgical therapies. More information about Spinal's therapies can be found at the business unit's patient education website, http://www.back.com
Medtronic plc (http://www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may d iffer materially from anticipated results.
AVILA ™ is CE Marked. AVILA™ is not approved in jurisdictions which do not recognize the CE Mark.
Published at Pharmiweb